Company profile: SwanBio Therapeutics
1.1 - Company Overview
Company description
- Provider of gene therapy focused on genetically defined therapies for neurological disorders. Offerings include SBT101, a candidate for adrenomyeloneuropathy targeting ABCD1 via AAV9; pipeline development in spinal cord-related indications; clinical trials, including a Phase 1/2 study of SBT101 and natural history studies of AMN; and patient and family resources, including trial information and compassionate use policies.
Products and services
- SBT101: AAV9-based clinical-grade gene therapy candidate targeting the disease-causing ABCD1 mutation to treat adrenomyeloneuropathy (AMN), engineered for precise, genetically defined intervention in neurological disease
- Clinical Trials: Clinical-stage program conducting a Phase 1/2 study of SBT101 and AMN natural history studies to evaluate the safety and efficacy of investigational drugs
- Pipeline Development: Genetically defined, neurology-focused pipeline advancing gene therapy candidates for well-defined disease areas with high unmet medical needs, emphasizing spinal cord-related indications and commercialization of therapeutics
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to SwanBio Therapeutics
Landos Biopharma
HQ: United States
Website
- Description: Provider of oral, first-in-class, locally acting small-molecule therapeutics for autoimmune diseases. Pipeline: NX-13 (NLRX1) for ulcerative colitis and Crohn’s; LABP-66 (NLRX1) for multiple sclerosis and neurodegenerative disorders; LABP-73 (NLRX1) for asthma and eosinophilic disorders; LABP-69 (PLXDC2) for rheumatoid arthritis, ulcerative colitis, and Crohn’s.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Landos Biopharma company profile →
Curemark
HQ: United States
Website
- Description: Provider of socially-driven biotechnology therapies for neurological diseases, developing CM-AT for Autism Spectrum Disorder (enhancing protein digestion and potentially restoring essential amino acids), CM-4612 (Phase III-ready for ADHD), CM-182 (enzyme replacement therapy for schizophrenia), CM-PK (for Parkinson’s, potentially affecting dopamine), and CM-1212 (for substance use disorders).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Curemark company profile →
Moberg
HQ: United States
Website
- Description: Provider of medical devices and neurodiagnostic solutions, including RetCam Envision pediatric ophthalmic imaging, Otoscan 3D ear scanning for auditory assessments, Natus NeuroWorks EEG analysis software, UltraPro S100 EMG/NCS/EP neurodiagnostic systems, and dedicated service and support for efficient workflows and optimal patient outcomes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Moberg company profile →
Impulse Monitoring
HQ: United States
Website
- Description: Provider of intraoperative neurophysiologic monitoring solutions to hospitals and other healthcare facilities, offering insight into the nervous system during spinal, nerve, and brain-related surgeries. Solutions include IONM delivering real-time data and alerts to help reduce surgical risk, plus EEG, ECoG, EMG, and SSEP for diagnosis and intraoperative monitoring.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Impulse Monitoring company profile →
Levicept
HQ: United Kingdom
Website
- Description: Provider of biological therapies for chronic pain, including LEVI-04 (p75NTR-Fc) for knee osteoarthritis that modulates the neurotrophin pathway to minimize side effects associated with anti-NGF antibodies, and a Phase II randomized, double-blind, placebo-controlled clinical trial assessing its efficacy, safety, and tolerability.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Levicept company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for SwanBio Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to SwanBio Therapeutics
2.2 - Growth funds investing in similar companies to SwanBio Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for SwanBio Therapeutics
4.2 - Public trading comparable groups for SwanBio Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →